{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:20:44Z","timestamp":1791764444930,"version":"4.3.4"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["113-2628-B-006-004"],"award-info":[{"award-number":["113-2628-B-006-004"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["114-2628-B-006-014"],"award-info":[{"award-number":["114-2628-B-006-014"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["114-2320-B-006-027-MY3"],"award-info":[{"award-number":["114-2320-B-006-027-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["EX113-11308BC"],"award-info":[{"award-number":["EX113-11308BC"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["EX114-11308BC"],"award-info":[{"award-number":["EX114-11308BC"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["EX115-11308BC"],"award-info":[{"award-number":["EX115-11308BC"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76725-8","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:44:56Z","timestamp":1786707896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TogoPhosTAC as a delivery-ready platform for targeted protein dephosphorylation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6242-9947","authenticated-orcid":false,"given":"Yu-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ting","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9016-2190","authenticated-orcid":false,"given":"Hong-Ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4622-3674","authenticated-orcid":false,"given":"Chun-Hsin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9471-4471","authenticated-orcid":false,"given":"Po-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"76725_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).","journal-title":"Mol. Cancer"},{"key":"76725_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa, C. et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct. Target. Ther. 9, 201 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76725_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.neuroscience.2012.01.028","volume":"207","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. Lewy-like aggregation of \u03b1-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 207, 288\u2013297 (2012).","journal-title":"Neuroscience"},{"key":"76725_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J., Lee, V. M. Y. & Trojanowski, J. Q. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat. Rev. Neurosci. 14, 626\u2013636 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"76725_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1750-1326-9-43","volume":"9","author":"S Moussaud","year":"2014","unstructured":"Moussaud, S. et al. Alpha-synuclein and tau: teammates in neurodegeneration? Mol. Neurodegener. 9, 43 (2014).","journal-title":"Mol. Neurodegener."},{"key":"76725_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.csbj.2014.09.011","volume":"12","author":"S Lim","year":"2014","unstructured":"Lim, S., Haque, M. M., Kim, D., Kim, D. J. & Kim, Y. K. Cell-based models to investigate tau aggregation. Comp. Struct. Biotechnol. J. 12, 7\u201313 (2014).","journal-title":"Comp. Struct. Biotechnol. J."},{"key":"76725_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neulet.2018.11.011","volume":"692","author":"KH Strang","year":"2019","unstructured":"Strang, K. H. et al. Phosphorylation of serine 305 in tau inhibits aggregation. Neurosci. Lett. 692, 187\u2013192 (2019).","journal-title":"Neurosci. Lett."},{"key":"76725_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem, S. S. et al. \u03b1-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl. Acad. Sci. USA 119, e2109617119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76725_CR9","doi-asserted-by":"publisher","unstructured":"Chen, H. R. et al. Intrahippocampal delivery of hyperphosphorylated human tau oligomers induces neurodegeneration in non-transgenic wildtype mice. Preprint at https:\/\/doi.org\/10.1101\/2025.03.10.642468 (2025).","DOI":"10.1101\/2025.03.10.642468"},{"key":"76725_CR10","doi-asserted-by":"publisher","first-page":"108107","DOI":"10.1016\/j.phrs.2026.108107","volume":"224","author":"R Roskoski","year":"2026","unstructured":"Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update. Pharmacol. Res. 224, 108107 (2026).","journal-title":"Pharmacol. Res."},{"key":"76725_CR11","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski","year":"2024","unstructured":"Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol. Res. 200, 107059 (2024).","journal-title":"Pharmacol. Res."},{"key":"76725_CR12","doi-asserted-by":"publisher","first-page":"116031","DOI":"10.1016\/j.ejmech.2023.116031","volume":"264","author":"M Guo","year":"2024","unstructured":"Guo, M. et al. Targeting phosphatases: From molecule design to clinical trials. Eur. J. Med. Chem. 264, 116031 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"76725_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.chembiol.2025.12.012","volume":"33","author":"D-T Ke","year":"2026","unstructured":"Ke, D.-T., Zhan, Z., Zhang, W., Hu, Z. & Chen, P.-H. Deciphering phosphorylation TACtics: Advances in phosphorylation targeting strategies and bifunctional modalities. Cell Chem. Biol. 33, 153\u2013168 (2026).","journal-title":"Cell Chem. Biol."},{"key":"76725_CR14","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","volume":"80","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 80, 4840\u20134853 (2020).","journal-title":"Cancer Res."},{"key":"76725_CR15","doi-asserted-by":"publisher","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","volume":"63","author":"X Yuan","year":"2020","unstructured":"Yuan, X., Bu, H., Zhou, J., Yang, C.-Y. & Zhang, H. Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application. J. Med. Chem. 63, 11368\u201311396 (2020).","journal-title":"J. Med. Chem."},{"key":"76725_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","volume":"50","author":"S-L Paiva","year":"2019","unstructured":"Paiva, S.-L. & Crews, C. M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 50, 111\u2013119 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"76725_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181, 102\u2013114 (2020).","journal-title":"Cell"},{"key":"76725_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76725_CR19","doi-asserted-by":"publisher","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","volume":"23","author":"Z Hu","year":"2022","unstructured":"Hu, Z. & Crews, C. M. Recent developments in PROTAC-mediated protein degradation: from bench to clinic. ChemBioChem 23, e202100270 (2022).","journal-title":"ChemBioChem"},{"key":"76725_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","volume":"16","author":"TM Nguyen","year":"2024","unstructured":"Nguyen, T. M. et al. Proteolysis-targeting chimeras with reduced off-targets. Nat. Chem. 16, 218\u2013228 (2024).","journal-title":"Nat. Chem."},{"key":"76725_CR21","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1021\/acs.jmedchem.9b01167","volume":"63","author":"S Yamazoe","year":"2020","unstructured":"Yamazoe, S. et al. Heterobifunctional molecules induce dephosphorylation of kinases\u2013a proof of concept study. J. Med. Chem. 63, 2807\u20132813 (2020).","journal-title":"J. Med. Chem."},{"key":"76725_CR22","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1021\/acschembio.1c00693","volume":"16","author":"P-H Chen","year":"2021","unstructured":"Chen, P.-H. et al. Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs). ACS Chem. Biol. 16, 2808\u20132815 (2021).","journal-title":"ACS Chem. Biol."},{"key":"76725_CR23","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1021\/jacs.2c11706","volume":"145","author":"Z Hu","year":"2023","unstructured":"Hu, Z. et al. Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality. J. Am. Chem. Soc. 145, 4045\u20134055 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj7251","volume":"10","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling. Sci. Adv. 10, eadj7251 (2024).","journal-title":"Sci. Adv."},{"key":"76725_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104307","volume":"30","author":"Q He","year":"2025","unstructured":"He, Q. et al. Modulating the phosphorylation status of target proteins through bifunctional molecules. Drug Discov. Today 30, 104307 (2025).","journal-title":"Drug Discov. Today"},{"key":"76725_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1021\/acsptsci.4c00733","volume":"8","author":"E Uliassi","year":"2025","unstructured":"Uliassi, E., Bolognesi, M. L. & Milelli, A. Targeting Tau protein with proximity inducing modulators: a new frontier to combat tauopathies. ACS Pharmacol. Transl. Sci. 8, 654\u2013672 (2025).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"76725_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41392-021-00669-2","volume":"6","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduct. Target. Ther. 6, 269 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76725_CR28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.chembiol.2024.09.003","volume":"31","author":"Y Xiao","year":"2024","unstructured":"Xiao, Y. et al. A tau dephosphorylation-targeting chimera selectively recruits protein phosphatase-1 to ameliorate Alzheimer\u2019s disease and tauopathies. Cell Chem. Biol. 31, 1787\u20131799 (2024).","journal-title":"Cell Chem. Biol."},{"key":"76725_CR29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1021\/jacs.2c10759","volume":"145","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Protein phosphatase 5-recruiting chimeras for accelerating apoptosis-signal-regulated kinase 1 dephosphorylation with antiproliferative activity. J. Am. Chem. Soc. 145, 1118\u20131128 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1021\/acschembio.5c00165","volume":"20","author":"J Gu","year":"2025","unstructured":"Gu, J. et al. Protein phosphatase 5-recruiting chimeras for accelerating Tau dephosphorylation. ACS Chem. Biol. 20, 1347\u20131360 (2025).","journal-title":"ACS Chem. Biol."},{"key":"76725_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cels.2018.06.006","volume":"7","author":"A Stanoev","year":"2018","unstructured":"Stanoev, A. et al. Interdependence between EGFR and phosphatases spatially established by vesicular dynamics generates a growth factor sensing and responding network. Cell Syst. 7, 295\u2013309 (2018).","journal-title":"Cell Syst."},{"key":"76725_CR32","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","volume":"31","author":"K-W Lee","year":"2011","unstructured":"Lee, K.-W. et al. Enhanced phosphatase activity attenuates \u03b1-synucleinopathy in a mouse model. J. Neurosci. 31, 6963 (2011).","journal-title":"J. Neurosci."},{"key":"76725_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/1873-3468.12907","volume":"592","author":"G Taleski","year":"2018","unstructured":"Taleski, G. & Sontag, E. Protein phosphatase 2A and tau: an orchestrated \u2018Pas de Deux\u2019. FEBS Lett. 592, 1079\u20131095 (2018).","journal-title":"FEBS Lett."},{"key":"76725_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50235-x","volume":"15","author":"A Chan","year":"2024","unstructured":"Chan, A. et al. Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins. Nat. Commun. 15, 5808 (2024).","journal-title":"Nat. Commun."},{"key":"76725_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.478","volume":"5","author":"X Xue","year":"2024","unstructured":"Xue, X. et al. mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation. MedComm (2020) 5, e478 (2024).","journal-title":"MedComm (2020)"},{"key":"76725_CR36","doi-asserted-by":"publisher","first-page":"27382","DOI":"10.1021\/jacs.4c06402","volume":"146","author":"X Teng","year":"2024","unstructured":"Teng, X. et al. ClickRNA-PROTAC for tumor-selective protein degradation and targeted cancer therapy. J. Am. Chem. Soc. 146, 27382\u201327391 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","volume":"14","author":"B Nabet","year":"2018","unstructured":"Nabet, B. et al. The dTAG system for immediate and target-specific protein degradation. Nat. Chem. Biol. 14, 431\u2013441 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"76725_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18377-w","volume":"11","author":"B Nabet","year":"2020","unstructured":"Nabet, B. et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat. Commun. 11, 4687 (2020).","journal-title":"Nat. Commun."},{"key":"76725_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29670-1","volume":"13","author":"C Grohmann","year":"2022","unstructured":"Grohmann, C. et al. Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms. Nat. Commun. 13, 2073 (2022).","journal-title":"Nat. Commun."},{"key":"76725_CR40","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"M-L Malarte","year":"2023","unstructured":"Malarte, M.-L. et al. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol. Psychiatr. 28, 1272\u20131283 (2023).","journal-title":"Mol. Psychiatr."},{"key":"76725_CR41","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth, H. et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur. J. Nucl. Med. Mol. Imaging 46, 2178\u20132189 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"76725_CR42","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.2967\/jnumed.123.265856","volume":"64","author":"G Blazhenets","year":"2023","unstructured":"Blazhenets, G. et al. [18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration. J. Nucl. Med. 64, 1980 (2023).","journal-title":"J. Nucl. Med."},{"key":"76725_CR43","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/emboj.2013.149","volume":"32","author":"S Sigismund","year":"2013","unstructured":"Sigismund, S. et al. Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J. 32, 2140\u20132157 (2013).","journal-title":"EMBO J."},{"key":"76725_CR44","doi-asserted-by":"publisher","first-page":"104503","DOI":"10.1016\/j.jprot.2022.104503","volume":"255","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. & Sakurai, H. New trend in ligand-induced EGFR trafficking: A dual-mode clathrin-mediated endocytosis model. J. Proteomics 255, 104503 (2022).","journal-title":"J. Proteomics"},{"key":"76725_CR45","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1073\/pnas.1520244113","volume":"113","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl. Acad. Sci. USA 113, 2868\u20132873 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76725_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acs.accounts.8b00493","volume":"52","author":"J Chang","year":"2019","unstructured":"Chang, J. et al. Integrating combinatorial lipid nanoparticle and chemically modified protein for intracellular delivery and genome editing. Acc. Chem. Res. 52, 665\u2013675 (2019).","journal-title":"Acc. Chem. Res."},{"key":"76725_CR47","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","volume":"330","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles. J. Control. Release 330, 1244\u20131249 (2021).","journal-title":"J. Control. Release"},{"key":"76725_CR48","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"76725_CR49","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1074\/jbc.RA120.014715","volume":"295","author":"B Han","year":"2020","unstructured":"Han, B. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands. J. Biol. Chem. 295, 15280\u201315291 (2020).","journal-title":"J. Biol. Chem."},{"key":"76725_CR50","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","volume":"111","author":"LA Parra-Rivas","year":"2023","unstructured":"Parra-Rivas, L. A. et al. Serine-129 phosphorylation of alpha-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function. Neuron 111, 4006\u20134023 (2023).","journal-title":"Neuron"},{"key":"76725_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00805-z","volume":"20","author":"G Nadel","year":"2022","unstructured":"Nadel, G. et al. GqPCR-stimulated dephosphorylation of AKT is induced by an IGBP1-mediated PP2A switch. Cell Commun. Signal. 20, 5 (2022).","journal-title":"Cell Commun. Signal."},{"key":"76725_CR52","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1074\/jbc.M709585200","volume":"283","author":"Y-C Kuo","year":"2008","unstructured":"Kuo, Y.-C. et al. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55\u03b1 regulatory subunit targeting of the protein phosphatase 2A poloenzyme to Akt*. J. Biol. Chem. 283, 1882\u20131892 (2008).","journal-title":"J. Biol. Chem."},{"key":"76725_CR53","doi-asserted-by":"publisher","first-page":"110776","DOI":"10.1016\/j.celrep.2022.110776","volume":"39","author":"BJ Tuck","year":"2022","unstructured":"Tuck, B. J. et al. Cholesterol determines the cytosolic entry and seeded aggregation of tau. Cell Rep 39, 110776 (2022).","journal-title":"Cell Rep"},{"key":"76725_CR54","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba, M. et al. Synthetic Tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer\u2019s-like tauopathy. J. Neurosci. 33, 1024 (2013).","journal-title":"J. Neurosci."},{"key":"76725_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00401-015-1458-4","volume":"130","author":"M Iba","year":"2015","unstructured":"Iba, M. et al. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC\u2019s afferent and efferent connections. Acta Neuropathol. 130, 349\u2013362 (2015).","journal-title":"Acta Neuropathol."},{"key":"76725_CR56","doi-asserted-by":"publisher","first-page":"974890","DOI":"10.3389\/fnmol.2022.974890","volume":"15","author":"RA DeGiosio","year":"2022","unstructured":"DeGiosio, R. A. et al. More than a marker: potential pathogenic functions of MAP2. Front. Mol. Neurosci. 15, 974890 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"76725_CR57","doi-asserted-by":"publisher","first-page":"e2316175121","DOI":"10.1073\/pnas.2316175121","volume":"121","author":"NE Mammeri","year":"2024","unstructured":"Mammeri, N. E., Dregni, A. J., Duan, P. & Hong, M. Structures of AT8 and PHF1 phosphomimetic tau: Insights into the posttranslational modification code of tau aggregation. Proc. Natl. Acad. Sci. USA 121, e2316175121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76725_CR58","doi-asserted-by":"publisher","first-page":"ar68","DOI":"10.1091\/mbc.E23-01-0024","volume":"34","author":"A Uchida","year":"2023","unstructured":"Uchida, A., Peng, J., Brown, A. & Gupton, S. Regulation of neurofilament length and transport by a dynamic cycle of phospho-dependent polymer severing and annealing. Mol. Biol. Cell 34, ar68 (2023).","journal-title":"Mol. Biol. Cell"},{"key":"76725_CR59","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.nbd.2014.08.016","volume":"71","author":"RA Quintanilla","year":"2014","unstructured":"Quintanilla, R. A., von Bernhardi, R., Godoy, J. A., Inestrosa, N. C. & Johnson, G. V. W. Phosphorylated tau potentiates A\u03b2-induced mitochondrial damage in mature neurons. Neurobiol. Dis. 71, 260\u2013269 (2014).","journal-title":"Neurobiol. Dis."},{"key":"76725_CR60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","volume":"48","author":"GA Jicha","year":"1997","unstructured":"Jicha, G. A., Bowser, R., Kazam, I. G. & Davies, P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128\u2013132 (1997).","journal-title":"J. Neurosci. Res."},{"key":"76725_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nprot.2007.44","volume":"2","author":"AA Walf","year":"2007","unstructured":"Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2, 322\u2013328 (2007).","journal-title":"Nat. Protoc."},{"key":"76725_CR62","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/nprot.2013.155","volume":"8","author":"M Leger","year":"2013","unstructured":"Leger, M. et al. Object recognition test in mice. Nat. Protoc. 8, 2531\u20132537 (2013).","journal-title":"Nat. Protoc."},{"key":"76725_CR63","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nprot.2006.116","volume":"1","author":"CV Vorhees","year":"2006","unstructured":"Vorhees, C. V. & Williams, M. T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848\u2013858 (2006).","journal-title":"Nat. Protoc."},{"key":"76725_CR64","doi-asserted-by":"publisher","first-page":"104572","DOI":"10.1016\/j.jbc.2023.104572","volume":"299","author":"Y Peng","year":"2023","unstructured":"Peng, Y., Liu, J., Inuzuka, H. & Wei, W. Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy. J. Biol. Chem. 299, 104572 (2023).","journal-title":"J. Biol. Chem."},{"key":"76725_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","volume":"14","author":"I Drath","year":"2025","unstructured":"Drath, I., Richter, F. & Feja, M. Nose-to-brain drug delivery: from bench to bedside. Transl. Neurodegener. 14, 23 (2025).","journal-title":"Transl. Neurodegener."},{"key":"76725_CR66","doi-asserted-by":"publisher","first-page":"115196","DOI":"10.1016\/j.addr.2024.115196","volume":"207","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv. Drug Del. Rev. 207, 115196 (2024).","journal-title":"Adv. Drug Del. Rev."},{"key":"76725_CR67","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.cell.2025.01.017","volume":"188","author":"H Shen","year":"2025","unstructured":"Shen, H. et al. Engineered commensals for targeted nose-to-brain drug delivery. Cell 188, 1545\u20131562 (2025).","journal-title":"Cell"},{"key":"76725_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48462-3","volume":"15","author":"I Diez","year":"2024","unstructured":"Diez, I. et al. Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging. Nat. Commun. 15, 4809 (2024).","journal-title":"Nat. Commun."},{"key":"76725_CR69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00401-025-02902-6","volume":"149","author":"M Dourte","year":"2025","unstructured":"Dourte, M. et al. The olfactory epithelium: a critical gateway for pathological tau propagation and a target for mitigating tauopathy in the central nervous system. Acta Neuropathol. 149, 64 (2025).","journal-title":"Acta Neuropathol."},{"key":"76725_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1208\/s12248-015-9724-x","volume":"17","author":"MJR Ruigrok","year":"2015","unstructured":"Ruigrok, M. J. R. & de Lange, E. C. M. Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans. AAPS J 17, 493\u2013505 (2015).","journal-title":"AAPS J"},{"key":"76725_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114946","volume":"395","author":"Y Lu","year":"2026","unstructured":"Lu, Y. et al. Precision nose-to-brain therapeutics: Advances in drug delivery systems and emerging preclinical models. J. Control. Release 395, 114946 (2026).","journal-title":"J. Control. Release"},{"key":"76725_CR72","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1021\/acs.nanolett.2c05056","volume":"23","author":"D Kou","year":"2023","unstructured":"Kou, D. et al. Intranasal pathway for nanoparticles to enter the central nervous system. Nano Lett. 23, 5381\u20135390 (2023).","journal-title":"Nano Lett."},{"key":"76725_CR73","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jconrel.2023.06.005","volume":"359","author":"K Sasaki","year":"2023","unstructured":"Sasaki, K. et al. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys. J. Control. Release 359, 384\u2013399 (2023).","journal-title":"J. Control. Release"},{"key":"76725_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70213","volume":"6","author":"Y Qiu","year":"2025","unstructured":"Qiu, Y. et al. The Nasal\u2013Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases. MedComm 6, e70213 (2025).","journal-title":"MedComm"},{"key":"76725_CR75","doi-asserted-by":"publisher","first-page":"9779","DOI":"10.1021\/jacs.3c14380","volume":"146","author":"B Ma","year":"2024","unstructured":"Ma, B. et al. Targeted protein O-GlcNAcylation using bifunctional small molecules. J. Am. Chem. Soc. 146, 9779\u20139789 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR76","doi-asserted-by":"publisher","first-page":"16700","DOI":"10.1021\/jacs.1c07850","volume":"143","author":"WW Wang","year":"2021","unstructured":"Wang, W. W. et al. Targeted protein acetylation in cells using heterobifunctional molecules. J. Am. Chem. Soc. 143, 16700\u201316708 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR77","doi-asserted-by":"publisher","first-page":"26028","DOI":"10.1021\/jacs.3c06179","volume":"145","author":"WJ Gibson","year":"2023","unstructured":"Gibson, W. J. et al. Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation. J. Am. Chem. Soc. 145, 26028\u201326037 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"76725_CR78","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","volume":"22","author":"F Liu","year":"2005","unstructured":"Liu, F., Grundke-Iqbal, I., Iqbal, K. & Gong, C.-X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942\u20131950 (2005).","journal-title":"Eur. J. Neurosci."},{"key":"76725_CR79","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","volume":"28","author":"N Basheer","year":"2023","unstructured":"Basheer, N. et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Mol. Psychiatr. 28, 2197\u20132214 (2023).","journal-title":"Mol. Psychiatr."},{"key":"76725_CR80","doi-asserted-by":"publisher","first-page":"13888","DOI":"10.1073\/pnas.1009038107","volume":"107","author":"J van Eersel","year":"2010","unstructured":"van Eersel, J. et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models. Proc. Natl. Acad. Sci. USA 107, 13888\u201313893 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76725_CR81","doi-asserted-by":"publisher","first-page":"21830","DOI":"10.1073\/pnas.0912793107","volume":"107","author":"E Kickstein","year":"2010","unstructured":"Kickstein, E. et al. Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. USA 107, 21830\u201321835 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76725_CR82","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1096\/fj.201802264R","volume":"33","author":"RM De Palma","year":"2019","unstructured":"De Palma, R. M. et al. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J 33, 7647\u20137666 (2019).","journal-title":"FASEB J"},{"key":"76725_CR83","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s12035-021-02613-5","volume":"59","author":"SG Fagan","year":"2022","unstructured":"Fagan, S. G., Bechet, S. & Dev, K. K. Fingolimod rescues memory and improves pathological hallmarks in the 3xTg-AD model of Alzheimer\u2019s disease. Mol. Neurobiol. 59, 1882\u20131895 (2022).","journal-title":"Mol. Neurobiol."},{"key":"76725_CR84","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2020.03.038","volume":"181","author":"D Leonard","year":"2020","unstructured":"Leonard, D. et al. Selective PP2A enhancement through biased heterotrimer stabilization. Cell 181, 688\u2013701 (2020).","journal-title":"Cell"},{"key":"76725_CR85","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s13311-020-00841-6","volume":"17","author":"H Wei","year":"2020","unstructured":"Wei, H. et al. Direct activation of protein phosphatase 2A (PP2A) by tricyclic sulfonamides ameliorates alzheimer\u2019s disease pathogenesis in cell and animal models. Neurotherapeutics 17, 1087\u20131103 (2020).","journal-title":"Neurotherapeutics"},{"key":"76725_CR86","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.pharmthera.2025.108834","volume":"269","author":"DA Neale","year":"2025","unstructured":"Neale, D. A., Morris, J. C., Verrills, N. M. & Ammit, A. J. Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeutics. Pharmacol. Ther. 269, 108834 (2025).","journal-title":"Pharmacol. Ther."},{"key":"76725_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110611","volume":"41","author":"G Vit","year":"2022","unstructured":"Vit, G. et al. Chemogenetic profiling reveals PP2A-independent cytotoxicity of proposed PP2A activators iHAP1 and DT-061. EMBO J. 41, EMBJ2022110611 (2022).","journal-title":"EMBO J."},{"key":"76725_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176093","volume":"135","author":"MA Lum","year":"2025","unstructured":"Lum, M. A. et al. Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells. J. Clin. Invest. 135, e176093 (2025).","journal-title":"J. Clin. Invest."},{"key":"76725_CR89","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.ajpath.2025.05.020","volume":"195","author":"A Djurovic-Topalovic","year":"2025","unstructured":"Djurovic-Topalovic, A., Horgan, N. G. & Fortin, J. S. Updates on Tau-related drug targets and potential disease-modifying therapies for Alzheimer disease. Am. J. Pathol. 195, 1975\u20131987 (2025).","journal-title":"Am. J. Pathol."},{"key":"76725_CR90","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","volume":"17","author":"GA Harris","year":"2025","unstructured":"Harris, G. A., Hirschfeld, L. R., Gonzalez, M. I., Pritchard, M. C. & May, P. C. Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials. Alzheimers Res. Ther. 17, 129 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"76725_CR91","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1021\/acschemneuro.5c00484","volume":"16","author":"X Feng","year":"2025","unstructured":"Feng, X. & Wang, H. Antibody therapies for Alzheimer\u2019s disease: a new strategy for targeted therapy and blood\u2013brain barrier delivery. ACS Chem. Neurosci. 16, 3450\u20133464 (2025).","journal-title":"ACS Chem. Neurosci."},{"key":"76725_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae100","volume":"6","author":"P Wongsodirdjo","year":"2024","unstructured":"Wongsodirdjo, P. et al. Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau. Brain Commun. 6, fcae100 (2024).","journal-title":"Brain Commun."},{"key":"76725_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0730","volume":"11","author":"D Cao","year":"2025","unstructured":"Cao, D. et al. Lipid nanoparticles for mRNA delivery in brain via systemic administration. Sci. Adv. 11, eadw0730 (2025).","journal-title":"Sci. Adv."},{"key":"76725_CR94","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","volume":"24","author":"C Wang","year":"2025","unstructured":"Wang, C. et al. Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. 24, 1653\u20131663 (2025).","journal-title":"Nat. Mater."},{"key":"76725_CR95","doi-asserted-by":"publisher","first-page":"102685","DOI":"10.1016\/j.xcrm.2026.102685","volume":"7","author":"Y Zou","year":"2026","unstructured":"Zou, Y., Sang, Y., Zheng, M. & Shi, B. Blood-brain barrier-penetrative lipid nanoparticles enable systemic delivery of TRIM11 mRNA to disaggregate Tau in Alzheimer\u2019s disease models. Cell Rep. Med. 7, 102685 (2026).","journal-title":"Cell Rep. Med."},{"key":"76725_CR96","doi-asserted-by":"publisher","first-page":"113641","DOI":"10.1016\/j.jconrel.2025.113641","volume":"381","author":"SG Moosavi","year":"2025","unstructured":"Moosavi, S. G., Rahiman, N., Jaafari, M. R. & Arabi, L. Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases. J. Control. Release 381, 113641 (2025).","journal-title":"J. Control. Release"},{"key":"76725_CR97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00701-024-06028-8","volume":"166","author":"A Perera","year":"2024","unstructured":"Perera, A., Brock, O., Ahmed, A., Shaw, C. & Ashkan, K. Taking the knife to neurodegeneration: a review of surgical gene therapy delivery to the CNS. Acta Neurochir. 166, 136 (2024).","journal-title":"Acta Neurochir."},{"key":"76725_CR98","doi-asserted-by":"publisher","first-page":"e00434","DOI":"10.1016\/j.neurot.2024.e00434","volume":"21","author":"RV Patel","year":"2024","unstructured":"Patel, R. V., Nanda, P. & Richardson, R. M. Neurosurgical gene therapy for central nervous system diseases. Neurotherapeutics 21, e00434 (2024).","journal-title":"Neurotherapeutics"},{"key":"76725_CR99","first-page":"100548","volume":"5","author":"M Tian","year":"2024","unstructured":"Tian, M., Ma, Z. & Yang, G.-Z. Micro\/nanosystems for controllable drug delivery to the brain. Innovation 5, 100548 (2024).","journal-title":"Innovation"},{"key":"76725_CR100","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.5c01070","volume":"23","author":"AC Amalraj","year":"2026","unstructured":"Amalraj, A. C. & Parthasarathy, V. Degraders on Demand: Engineering Smart Nanocarriers for PROTAC Delivery. Mol. Pharm. 23, 622\u2013638 (2026).","journal-title":"Mol. Pharm."},{"key":"76725_CR101","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41565-025-02081-1","volume":"21","author":"Y Liu","year":"2026","unstructured":"Liu, Y. et al. Nanoparticle-mediated targeting chimeras transform targeted protein degradation. Nat. Nanotechnol. 21, 176\u2013183 (2026).","journal-title":"Nat. Nanotechnol."},{"key":"76725_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2026.102764","volume":"36","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Intranasal delivery of Odorranalectin-modified lipid nanoparticles for multi-targeted therapy of Alzheimer\u2019s disease. Mater. Today Bio 36, 102764 (2026).","journal-title":"Mater. Today Bio"},{"key":"76725_CR103","doi-asserted-by":"publisher","first-page":"2408908","DOI":"10.1002\/advs.202408908","volume":"12","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. Nanoodor Particles Deliver Drugs to Central Nervous System via Olfactory Pathway. Adv. Sci. 12, 2408908 (2025).","journal-title":"Adv. Sci."},{"key":"76725_CR104","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1016\/j.apsb.2025.02.035","volume":"15","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged \u03b2-amyloid nanoscavenger for Alzheimer\u2019s disease therapy. Acta Pharm. Sin. B 15, 2884\u20132899 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"76725_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57488-0","volume":"16","author":"X Bian","year":"2025","unstructured":"Bian, X. et al. Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. Nat. Commun. 16, 2368 (2025).","journal-title":"Nat. Commun."},{"key":"76725_CR106","first-page":"100521","volume":"11","author":"B Alwali","year":"2026","unstructured":"Alwali, B., Parumasivam, T. & Al-Tabakha, M. M. Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies. Int. J. Pharm. X 11, 100521 (2026).","journal-title":"Int. J. Pharm. X"},{"key":"76725_CR107","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1021\/acs.molpharmaceut.3c00639","volume":"21","author":"A Maaz","year":"2024","unstructured":"Maaz, A., Blagbrough, I. S. & De Bank, P. A. A cell-based nasal model for screening the deposition, biocompatibility, and transport of aerosolized PLGA nanoparticles. Mol. Pharm. 21, 1108\u20131124 (2024).","journal-title":"Mol. Pharm."},{"key":"76725_CR108","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","volume":"327","author":"M Agrawal","year":"2020","unstructured":"Agrawal, M. et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J. Control. Release 327, 235\u2013265 (2020).","journal-title":"J. Control. Release"},{"key":"76725_CR109","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa2508681","volume":"394","author":"J Muenzer","year":"2026","unstructured":"Muenzer, J. et al. An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II. N. Engl. J. Med. 394, 39\u201350 (2026).","journal-title":"N. Engl. J. Med."},{"key":"76725_CR110","doi-asserted-by":"publisher","first-page":"100214","DOI":"10.1016\/j.tjpad.2025.100214","volume":"12","author":"D Sehlin","year":"2025","unstructured":"Sehlin, D. et al. Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 12, 100214 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"76725_CR111","doi-asserted-by":"publisher","first-page":"116038","DOI":"10.1016\/j.celrep.2025.116038","volume":"44","author":"RC Wells","year":"2025","unstructured":"Wells, R. C. et al. Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules. Cell Rep 44, 116038 (2025).","journal-title":"Cell Rep"},{"key":"76725_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads3204","volume":"389","author":"ME Pizzo","year":"2025","unstructured":"Pizzo, M. E. et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science 389, eads3204 (2025).","journal-title":"Science"},{"key":"76725_CR113","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker, S. J. et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci. Transl. Med. 16, eadi2245 (2024).","journal-title":"Sci. Transl. Med."},{"key":"76725_CR114","doi-asserted-by":"publisher","first-page":"170771","DOI":"10.1016\/j.cej.2025.170771","volume":"526","author":"X Kong","year":"2025","unstructured":"Kong, X. et al. TfR-aptamer programmed DNA nanoflowers penetrate the blood-brain barrier for synergistic NLRP3 silencing and neuroinflammation therapy. Chem. Eng. J. 526, 170771 (2025).","journal-title":"Chem. Eng. J."},{"key":"76725_CR115","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1021\/acschemneuro.5c00718","volume":"17","author":"TK Ponduri","year":"2026","unstructured":"Ponduri, T. K., Guntupalli, C., Jeganathan, B. & Malothu, N. Transferrin-functionalized chitosan nanoparticles enable intranasal brain delivery of cariprazine with enhanced neuropharmacological efficacy. ACS Chem. Neurosci. 17, 701\u2013718 (2026).","journal-title":"ACS Chem. Neurosci."},{"key":"76725_CR116","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1021\/acsnano.3c10674","volume":"18","author":"S Zha","year":"2024","unstructured":"Zha, S. et al. Functionalized nanomaterials capable of crossing the blood-brain barrier. ACS Nano 18, 1820\u20131845 (2024).","journal-title":"ACS Nano"},{"key":"76725_CR117","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1021\/acs.nanolett.4c05186","volume":"25","author":"EL Han","year":"2025","unstructured":"Han, E. L. et al. Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain. Nano Lett. 25, 800\u2013810 (2025).","journal-title":"Nano Lett."},{"key":"76725_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc7031","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci. Adv. 6, eabc7031 (2020).","journal-title":"Sci. Adv."},{"key":"76725_CR119","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s11095-022-03241-x","volume":"39","author":"E Puris","year":"2022","unstructured":"Puris, E., Fricker, G. & Gynther, M. Targeting transporters for drug delivery to the brain: can we do better? Pharm. Res. 39, 1415\u20131455 (2022).","journal-title":"Pharm. Res."},{"key":"76725_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58746-x","volume":"16","author":"K Tang","year":"2025","unstructured":"Tang, K. et al. Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions. Nat. Commun. 16, 3410 (2025).","journal-title":"Nat. Commun."},{"key":"76725_CR121","doi-asserted-by":"publisher","first-page":"36106","DOI":"10.1021\/acsnano.4c15013","volume":"19","author":"M Sela","year":"2025","unstructured":"Sela, M. et al. AI-Validated brain targeted mRNA lipid nanoparticles with neuronal tropism. ACS Nano 19, 36106\u201336128 (2025).","journal-title":"ACS Nano"},{"key":"76725_CR122","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12668-026-02476-x","volume":"16","author":"NI Okafor","year":"2026","unstructured":"Okafor, N. I., Igbokwe, N., Onohuean, H., Faya, M. & Choonara, Y. E. Artificial intelligence-driven development and characterization of nanomedicine. BioNanoScience 16, 255 (2026).","journal-title":"BioNanoScience"},{"key":"76725_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/srep44102","volume":"7","author":"H Trzeciakiewicz","year":"2017","unstructured":"Trzeciakiewicz, H. et al. A dual pathogenic mechanism links Tau acetylation to sporadic tauopathy. Sci. Rep. 7, 44102 (2017).","journal-title":"Sci. Rep."},{"key":"76725_CR124","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1093\/hmg\/ddz151","volume":"28","author":"EJ Koller","year":"2019","unstructured":"Koller, E. J. et al. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum. Mol. Genet. 28, 3255\u20133269 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"76725_CR125","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1042\/BCJ20190042","volume":"476","author":"JS Rane","year":"2019","unstructured":"Rane, J. S., Kumari, A. & Panda, D. An acetylation mimicking mutation, K274Q, in tau imparts neurotoxicity by enhancing tau aggregation and inhibiting tubulin polymerization. Biochem. J. 476, 1401\u20131417 (2019).","journal-title":"Biochem. J."},{"key":"76725_CR126","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1073\/pnas.0500167102","volume":"102","author":"T Yamane","year":"2005","unstructured":"Yamane, T., Dylla, S. J., Muijtjens, M. & Weissman, I. L. Enforced Bcl-2 expression overrides serum and feeder cell requirements for mouse embryonic stem cell self-renewal. Proc. Natl. Acad. Sci. USA 102, 3312\u20133317 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76725-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76725-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76725-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:03:08Z","timestamp":1789383788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76725-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76725"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76725-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: P.H.C., H.R.C., Y.Y.C., and D.T.K. are inventors on a provisional patent application (USPTO Application# 64\/061,412) related to the technologies described in this work. Apart from this, the authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9772"}}